靶点- |
作用机制- |
|
|
在研适应症- |
非在研适应症- |
最高研发阶段临床1期 |
首次获批国家/地区- |
首次获批日期- |
Double-blind, Placebo-controlled, Ascending Single- and Multiple- Dose Study of the Safety, Tolerability, and Pharmacokinetics of NUV001 Administered Orally to Healthy Adult Participants
This blinded placebo-controlled study is designed to evaluate the safety, tolerability, and PK in healthy participants of a single- and multiple-doses (SAD and MAD) of a new investigational drug: NUV001
100 项与 Nuvamid SA 相关的临床结果
0 项与 Nuvamid SA 相关的专利(医药)
100 项与 Nuvamid SA 相关的药物交易
100 项与 Nuvamid SA 相关的转化医学